A Case Report of Sustained Cytokine Release Syndrome Due to Glofitamab and Literature Review
{{output}}
Glofitamab is a novel bispecific antibody targeting CD20×CD3, capable of simultaneously targeting CD20 and CD3 to activate T cells and release cytotoxic proteins that kill cancer cells. Cytokine release syndrome (CRS) is one of the most common adverse events ... ...
